Yamazaki Susumu, Endo Amane, Iso Takashi, Abe Shinpei, Aoyagi You, Suzuki Mitsuyoshi, Fujii Toru, Haruna Hidenori, Ohtsuka Yoshikazu, Shimizu Toshiaki
Department of Pediatrics and Adolescent Medicine, Juntendo University Graduate School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
BMC Res Notes. 2015 Sep 28;8:487. doi: 10.1186/s13104-015-1520-2.
The role of cytomegalovirus infection in triggering systemic lupus erythematosus remains a subject of debate. Here, we present a case of childhood systemic lupus erythematosus with concomitant cytomegalovirus infection, which sheds light on the relationship between these conditions and their treatment in pediatric patients.
A 12-year-old Japanese girl with no history of systemic illness was diagnosed with systemic lupus erythematosus and concomitant primary cytomegalovirus infection. Her anti-cytomegalovirus immunoglobulin G antibodies were elevated during diagnosis and treatment. Further, the patient's cytomegalovirus pp65 antigenemia level was slightly elevated (1 cell per 5 × 10(4) cells). Treatment included the administration of ganciclovir, prednisolone, methylprednisolone, and cyclophosphamide, none of which prompted adverse effects. The patient was in good condition at the most recent follow-up.
Ganciclovir treatment is not completely safe, and there are no clinical guidelines regarding its use in patients with systemic lupus erythematosus triggered by cytomegalovirus infection. Our experience with this case suggests that the decision to administer ganciclovir treatment in pediatric cases should be guided by a variety of factors in addition to the cytomegalovirus antigenemia level. These factors include lymphopenia, renal biopsy results, and cytomegalovirus DNA levels detected by polymerase chain reaction. The details of our patient's presentation and treatment should prove illustrative to other clinicians who face similar cases.
巨细胞病毒感染在引发系统性红斑狼疮中的作用仍是一个有争议的话题。在此,我们报告一例儿童系统性红斑狼疮合并巨细胞病毒感染的病例,这为小儿患者中这些病症之间的关系及其治疗提供了线索。
一名12岁无全身性疾病史的日本女孩被诊断为系统性红斑狼疮合并原发性巨细胞病毒感染。在诊断和治疗期间,她的抗巨细胞病毒免疫球蛋白G抗体升高。此外,患者的巨细胞病毒pp65抗原血症水平略有升高(每5×10⁴个细胞中有1个细胞)。治疗包括给予更昔洛韦、泼尼松龙、甲泼尼龙和环磷酰胺,均未引发不良反应。在最近一次随访时患者状况良好。
更昔洛韦治疗并非完全安全,且对于其在巨细胞病毒感染引发的系统性红斑狼疮患者中的使用尚无临床指南。我们对该病例的经验表明,在儿科病例中决定给予更昔洛韦治疗时,除了巨细胞病毒抗原血症水平外,还应考虑多种因素。这些因素包括淋巴细胞减少、肾活检结果以及通过聚合酶链反应检测到的巨细胞病毒DNA水平。我们患者的临床表现和治疗细节应对面临类似病例的其他临床医生具有借鉴意义。